Motley Fool Australia

Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $1.46 billion
P/E Ratio 68.97
Dividend Yield 0.08%
Shares Outstanding 49.41 million
Earnings per share 0.436
Dividend per share 0.03
Year To Date Return 34.95%
Earnings Yield 1.45%
Franking N/A

Clinuvel Pharmaceuticals Limited (ASX: CUV) Latest News

falling healthcare asx share price Mesoblast capital raising

Clinuvel (ASX:CUV) share price drops on strategic update

More »

laboratory microscope

Clinuvel (ASX:CUV) share price falls despite positive update

More »

Falling ASX share price represented by shocked Investor looking at phone

ASX 200 Weekly Wrap: Inflation fears hold ASX down

More »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

These were the best performers on the ASX 200 last week

More »

ASX 200 news represented by Labrador dog holding a newspaper

ASX 200 Weekly Wrap: Calm restored to the ASX 200

More »

Young woman in yellow striped top with laptop raises arm in victory

These were the best performing ASX 200 shares last week

More »

Red and white arrows showing share price drop

Clinuvel (ASX:CUV) share price down despite recording 10th consecutive net profit

More »

falling healthcare asx share price Mesoblast capital raising

Clinuvel (ASX:CUV) share price pinches down after Israeli breakthrough

More »

Dividend Payment History

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

Yearly Dividend Payment Chart

Data provided by Morningstar.

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size
 

About Clinuvel Pharmaceuticals Ltd (ASX: CUV)

Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company that develops drugs for the treatment of a range of skin disorders. The company’s flagship product is Scenesse, a drug designed for the treatment of erythropoietic protoporphyria (EPP). EPP is a rare metabolic disorder which causes burns after brief exposure to visible light, especially sunlight. It is estimated that there are 5,000 to 10,000 EPP patients worldwide. 

Clinuvel is also seeking to progress the use of Scenesse for the treatment of vitiligo, a skin disorder characterised by the appearance of white to off-white skin patches due to the loss of melanin production.

The company’s history dates back to 1987 when university researchers devised an idea of synthesising human hormones to protect the skin. Clinuvel shares have been listed on the ASX since 2001 and as a biopharmaceutical company, the Clinuvel share price can often be particularly volatile, bouncing around in response to announcements such as clinical trials and new launches.

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
12 Apr 2021 $29.45 $-0.67 -2.22% 120,551 $30.12 $30.27 $29.23
09 Apr 2021 $30.12 $0.33 1.11% 92,793 $29.81 $30.61 $29.79
08 Apr 2021 $29.79 $1.17 4.09% 112,813 $28.64 $30.00 $28.32
07 Apr 2021 $28.62 $0.44 1.56% 82,022 $28.18 $28.93 $27.82
06 Apr 2021 $28.18 $0.54 1.95% 56,203 $28.30 $28.82 $27.74
01 Apr 2021 $27.64 $0.57 2.11% 50,968 $26.90 $27.75 $26.50
31 Mar 2021 $27.07 $0.07 0.26% 120,111 $26.79 $27.48 $26.39
30 Mar 2021 $27.00 $-0.68 -2.46% 85,286 $27.51 $27.96 $26.97
29 Mar 2021 $27.68 $-0.59 -2.09% 41,365 $28.42 $28.50 $27.68
26 Mar 2021 $28.27 $-0.21 -0.74% 109,176 $28.40 $28.96 $28.02
25 Mar 2021 $28.48 $0.57 2.04% 92,577 $27.95 $28.78 $27.51
24 Mar 2021 $27.91 $-0.73 -2.55% 104,903 $28.00 $28.38 $27.63
23 Mar 2021 $28.64 $0.70 2.51% 112,877 $28.02 $28.80 $27.98
22 Mar 2021 $27.94 $-0.35 -1.24% 92,359 $28.04 $28.78 $27.68
19 Mar 2021 $28.29 $0.97 3.55% 188,822 $27.30 $28.43 $27.07
18 Mar 2021 $27.32 $-0.14 -0.51% 121,381 $27.02 $27.70 $26.99
17 Mar 2021 $27.46 $0.82 3.08% 142,204 $26.54 $27.69 $26.24
16 Mar 2021 $26.64 $0.24 0.91% 119,378 $26.60 $27.00 $26.43
15 Mar 2021 $26.40 $1.10 4.35% 140,256 $25.55 $26.75 $25.05
Show more

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Mar 2021 Philippe Wolgen Sell 104 $2,564,744
02 Mar 2021 Jeffrey Rosenfeld Buy 670 $14,898
10 Sep 2020 Susan (Sue) Smith Buy 420 $8,988
26 Aug 2020 Philippe Wolgen Issued 1 $35,164,412


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Ms Brenda Mary Shanahan Non-Executive Director Dec 2007
Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
Dr Philippe J Wolgen Chief Executive Officer,Managing Director Dec 2005
Mr Willem A Blijdorp Non-Executive Director,Non-Executive Chairman Jan 2015
Dr Karen Agersborg Non-Executive Director Jan 2018
Dr Jeffrey Rosenfeld Non-Executive Director Nov 2019
Mr Darren Keamy Chief Finance Officer,Company Secretary Dec 2005
Darren Keamy Chief Finance Officer,Company Secretary
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 14,860,373 30.08%
HSBC Custody Nominees (Australia) Limited 9,877,178 19.99%
Acn 108 768 896 Pty Ltd 4,324,693 8.75%
Ender 1 Llc 2,590,824 5.24%
Citicorp Nominees Pty Limited 1,540,396 3.12%
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retail Client) 1,002,756 2.03%
National Nominees Limited 636,062 1.29%
M Badcock And P Chu Superannuation Fund Pty Ltd 628,447 1.27%
Dr Mark Edwin Badcock 567,890 1.15%
Bnp Paribas Noms Pty Ltd (Drp) 557,672 1.13%
National Nominees Limited (Db A/C) 481,667 0.97%
Merrill Lynch (Australia) Nominees Pty Limited 323,059 0.65%
BNP Paribas Noms (NZ) Ltd (DRP) 261,411 0.53%
Mr David William Trevorrow 222,222 0.45%
Bnp Paribas Nominees Pty Ltd (Agency Lending Drp A/C 220,669 0.45%
Bnp Paribas Nominees Pty Ltd (Lgt Bank Ag Drp) 213,770 0.43%
Vulcancrest Pty Ltd (The Vulancrets A/C) 200,000 0.40%
Ms Nicoletta Muner 187,625 0.38%
Hsbc Custody Nominees (Australia) Limited AA/C 2 187,000 0.38%
Mr David John Lewis 183,165 0.37%
Show more

FAQ

Will Clinuvel Pharmaceuticals pay a dividend in 2020?

Clinuvel Pharmaceuticals listed on the ASX in 2001 and only recently declared a profit for the first time in FY2017. Since then, the company went on to achieve increased profits across both FY2018 and FY2019. It also distributed final dividends of 2 cents and 2.5 cents per share for FY2018 and FY2019 respectively. As at 17 June 2020, Clinuvel has made no announcements regarding the status of its FY2020 dividend payment.

Does Clinuvel Pharmaceuticals offer a DRP?

Having only started paying dividends over the last couple of years, Clinuvel Pharmaceuticals does not currently offer a dividend reinvestment plan.